Myosin Therapeutics, a Jupiter, FL-based biotechnology company providing a platform for molecular entities, raised an undisclosed amount in Seed funding.
The round was led by Mint12 Pharma, LLC, with participation from the University of Florida Ventures, DeepWork Capital, and the Florida Opportunity Fund.
Founded in 2020 by Drs. Courtney Miller, Patrick Griffin, and Theodore Kamenecka, Myosin Therapeutics is developing its lead compound, MT-125, to treat glioblastoma, which is an aggressive form of brain cancer with a 95% fatality rate and limited treatment options available. In early models, MT-125 has shown that it can simultaneously arrest cancer cell division and migration, and therefore could be a first-in-class therapy.
The company intends to use the funds to reach IND filing for MT-125.
FinSMEs
15/03/2023